Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-10-23-Speech-2-313-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-10-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:Protocol to the Euro-Mediterranean Agreement establishing an association between the EC and Israel on Conformity Assessment and Acceptance of Industrial Products (CAA) (debate)2
dcterms:Language	"lv"^^xsd:language2
lpv:document identification number	"en.20121023.17.2-313-000"2
lpv:hasSubsequent	lp_eu:2012-10-23-Speech-2-314-0002
lpv:speaker	lp:Inese Vaidere2
lpv:spokenAs	substitute; Delegation to the Euro-Latin American Parliamentary Assembly (2009-09-16--2014-06-30)3 substitute; Delegation to the Euronest Parliamentary Assembly (2009-09-16--2014-06-30)3 substitute; Delegation to the EU-Ukraine Parliamentary Cooperation Committee (2009-09-16--2014-06-30)3 member; DROI (2012-01-19--2014-06-30)3 unknown; Vienotība (2012-07-04--2014-06-30)3 member; AFET (2012-01-19--2014-06-30)3 substitute; INTA (2012-01-19--2014-06-30)3 member; Delegation to the EU-Kazakhstan, EU-Kyrgyzstan and EU-Uzbekistan Parliamentary Cooperation Committees, and for relations with Tajikistan, Turkmenistan and Mongolia (2009-09-16--2014-06-30)3 member_of_the_bureau; EPP (2009-07-24--2014-06-30)3
lpv:translated text	"Mr President, ladies and gentlemen, an additional protocol on bilateral cooperation between the European Union and Israel is mutually beneficial and extremely important. It will improve access to cheap, generic medicines, eliminating technical restrictions. Israel’s medicines are among the best in the world, and many medical establishments use them, including most European health care bodies. The Protocol will speed up the long certification procedure, reducing costs and improving access to drugs, making it possible for patients to pay less. This, particularly in the current crisis, is very important to each of our citizens. The highest level of drug quality control will be retained, as demanded by European regulatory bodies. The Protocol also covers opportunities to export European drug products to Israel. At a time when we are talking about support for innovation, this would ensure real support for the largest innovation sector, pharmaceuticals. Thus it would lead to jobs and growth, too. The Protocol would also serve as a first step in other sectors of industry, in order to harmonise European and Israeli legislation. By bringing in a common certification system, we could reduce the cost of importing generic drugs by as much as EUR 10 billion per year, and the new certification procedures will ensure that only Israeli companies that are registered and approved by the European Union will be able to produce drugs for export. Thus only the best tested drugs will reach the European market. Businesses, which will be subject to the one-off certification procedure, will reduce production time to as little as three years. The economic gain from the Protocol is obvious. There is another gain: support for a democratic regime in this region torn apart by conflict and violence. I can only agree with Mr Caspary that if we conclude an agreement with Palestine, then we should do the same with Israel. I call upon my fellow Members to support the adoption of the Protocol without delay. Thank you."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph